All News
Pfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article
Janssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read Article
Creaky Joints Presentations at the ACR16 Meeting
CreakyJoints will be presenting 5 Posters at the 2016 ACR/AHRP Annual Meeting. At the meeting they will also announce the publication of first-ever Rheumatoid Arthritis Patient Guidelines.
Read Article
Amgen Highlights Enbrel, Prolia and Amjevita Research at ACR 2016
Amgen has released the presentation times and locations for 21 abstracts to be presented at the ACR/ARHP 2016 Annual Meeting in Washington next week.
Read Article
Genentech Presents New Data on Actemra & Rituxan at ACR 2016
At the upcoming 2016 ACR/ARHP Annual Meeting, Genentech will present 15 oral presentations from 17 abstracts relating to the use of tocilizumab and rituximab in a number of varied autoimmune conditions.
Read Article
Crescendo and Vectra Presentations at ACR 2016
Crescendo Bioscience has announced that it will have 4 poster presentations at the American College of Rheumatology 2016 Annual Meeting next week.
Read Article
10 Tips for Immunization in Practice
Dr. Jerome Greenberg from UCLA has published 10 tips and pearls (based on years of teaching and experience) on immunizations in an out-patient practice:
Read Article
RheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read Article
ACP Gout Guidelines Reviewed and Critiqued by Rheumatologists
ACP released clinical practice guidelines for the diagnosis and management of gout. Interestingly, these are not always aligned with the 2012 ACR gout guidelines.
Read Article
Prevalence of Inflammatory Bowel Disease Increases
The MMWR has reported that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), previously (1999) had an estimated 1.8 million (0.9%) prevalence. But as of 2015, an estimated 3.1 million (1.3%) of U.S.
Read Article
The RheumNow Week in Review – 28 October 2016
Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com
Read Article
October-September 2016 Top Social Media News
Following is a list of top tweets in September and October 2016; they were selected based on the number of clicks, retweets and likes by the viewership. More than 40,000 people were reached with the first one on our list.
Read Article
RheumNow Week in Review – 21 October 2016
Dr. Cush Reviews Highlights from the past week on RheumNow.com. Register to receive free daily rheumatology news written by rheumatologists for rheumatologists. Download the podcast at iTunes.com.
Read Article
RheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Read Article
Michelle Petri Reviews New Therapies for Lupus
In this video, Michelle Petri, MD, director of the Hopkins Lupus Center at Johns Hopkins University, discusses recent successes and challenges in the treatment of systemic lupus erythematosus, with clinical trials results ranging from "wildly positive" to "completely negative."
Read Article
My Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).
Those with Osteoporotic Fractures are Going Untreated
The International Osteoporosis Foundation (IOF) reports that nearly 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures.
Read Article
New Criteria for the Cryopyrinopathies (CAPS)
The diagnosis of periodic fevers is unified by undiagnosed but recurrent fever. Unfortunately the diagnosis of these disorders is hampered by their infrequency, protean features and a lack of clear criteria. Even more problematic is knowing who should be tested and for which monogenic marker?
Read Article
RheumNow Week in Review – 7 October 2016
Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.
Read Article
